Literature DB >> 28657969

Varicella-related Primary Health-care Visits, Hospitalizations and Mortality in Norway, 2008-2014.

Grazina Mirinaviciute1, Erle Kristensen, Britt Nakstad, Elmira Flem.   

Abstract

BACKGROUND: Norway does not currently implement universal varicella vaccination in childhood. We aimed to characterize health care burden of varicella in Norway in the prevaccine era.
METHODS: We linked individual patient data from different national registries to examine varicella vaccinations and varicella-coded primary care consultations, hospitalizations, outpatient hospital visits, deaths and viral infections of central nervous system in the whole population of Norway during 2008-2014. We estimated health care contact rates and described the epidemiology of medically attended varicella infection.
RESULTS: Each year approximately 14,600 varicella-related contacts occurred within primary health care and hospital sector in Norway. The annual contact rate was 221 cases per 100,000 population in primary health care and 7.3 cases per 100,000 in hospital care. Both in primary and hospital care, the highest incidences were observed among children 1 year of age: 2,654 and 78.1 cases per 100,000, respectively. The annual varicella mortality was estimated at 0.06 deaths per 100,000 and in-hospital case-fatality rate at 0.3%. Very few (0.2-0.5%) patients were vaccinated against varicella. Among hospitalized varicella patients, 22% had predisposing conditions, 9% had severe-to-very severe comorbidities and 5.5% were immunocompromised. Varicella-related complications were reported in 29.3% of hospitalized patients. Varicella zoster virus was the third most frequent virus found among 16% of patients with confirmed viral infections of central nervous system.
CONCLUSIONS: Varicella causes a considerable health care burden in Norway, especially among children. To inform the policy decision on the use of varicella vaccination, a health economic assessment of vaccination and mathematical modeling of vaccination impact are needed.

Entities:  

Mesh:

Year:  2017        PMID: 28657969     DOI: 10.1097/INF.0000000000001656

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

1.  Effectiveness and impact of a single-dose vaccine against chickenpox in the community of Madrid between 2001 and 2015.

Authors:  Pello Latasa; Angel Gil de Miguel; Maria Dolores Barranco Ordoñez; Inmaculada Rodero Garduño; Juan Carlos Sanz Moreno; María Ordobás Gavín; María Esteban Vasallo; Macarena Garrido-Estepa; Luis García-Comas
Journal:  Hum Vaccin Immunother       Date:  2018-06-22       Impact factor: 3.452

2.  Immunity to varicella zoster virus among pregnant women in the Norwegian Mother and Child Cohort Study.

Authors:  Grazina Mirinaviciute; Regine Barlinn; Susanne Gjeruldsen Dudman; Elmira Flem
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

3.  Economic burden of varicella in Europe in the absence of universal varicella vaccination.

Authors:  Manjiri Pawaskar; Estelle Méroc; Salome Samant; Elmira Flem; Goran Bencina; Margarita Riera-Montes; Ulrich Heininger
Journal:  BMC Public Health       Date:  2021-12-21       Impact factor: 3.295

4.  Economic evaluation of varicella vaccination strategies in Jiangsu province, China: a decision-tree Markov model.

Authors:  Qiang Wang; Shixin Xiu; Liuqing Yang; Jinxin Huang; Tingting Cui; Naiyang Shi; Xuwen Wang; Yuan Shen; Enpin Chen; Bing Lu; Hui Jin; Leesa Lin
Journal:  Hum Vaccin Immunother       Date:  2021-08-06       Impact factor: 4.526

5.  Clinical and economic impact of universal varicella vaccination in Norway: A modeling study.

Authors:  Manjiri Pawaskar; Colleen Burgess; Mathew Pillsbury; Torbjørn Wisløff; Elmira Flem
Journal:  PLoS One       Date:  2021-07-08       Impact factor: 3.240

6.  Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children.

Authors:  Giacomo Casabona; Md Ahsan Habib; Michael Povey; Marianne A Riise Bergsaker; Carl-Erik Flodmark; Ketil Arne Espnes; Camilla Tøndel; Sven-Arne Silfverdal
Journal:  Acta Paediatr       Date:  2021-10-28       Impact factor: 4.056

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.